Antiplatelet therapy and progression of coronary artery disease: a placebo-controlled trial with angiographic and clinical follow-up after myocardial infarction

American Heart Journal

Volumn 153, Issue 1, 2007, Pages 66.e1-66.e8

  Dieker, Hendrik Jan ^a   French, John K ^b,c   Joziasse, Irene C ^a   Brouwer, Marc A ^a   Elliott, John ^d   West, Teena M ^b   Webber, Bruce J ^b   Verheugt, Freek W A ^a   White, Harvey D ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AUCKLAND CITY HOSPITAL   (New Zealand)

^c LIVERPOOL HOSPITAL   (Australia)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANTITHROMBOCYTIC AGENT; PLACEBO;

ANGIOCARDIOGRAPHY; ARTERY OCCLUSION; ARTICLE; BLOOD VESSEL DIAMETER; CINEANGIOCARDIOGRAPHY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEATH; FOLLOW UP; HEART INFARCTION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION;

EID: 33845447275     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.10.006     Document Type: Article

References (30)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
2. Ohman E.M., Califf R.M., Topol E.J., et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. TAMI Study Group. Circulation 82 (1990) 781-791
3. Gibson C.M., Karha J., Murphy S.A., et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the thrombolysis in myocardial infarction trials. J Am Coll Cardiol 42 (2003) 7-16
4. Roux S., Christeller S., and Lüdin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after thrombolysis: a meta-analysis. J Am Coll Cardiol 19 (1992) 671-677
5. Meijer A., Verheugt F.W.A., Werter C.J.P.J., et al. Aspirin versus coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: a prospective placebo-controlled angiographic study: results of the APRICOT Study. Circulation 87 (1993) 1524-1530
6. White H.D., French J.K., Hamer A.W., et al. Frequent reocclusion of patent infarct-related arteries between 4 weeks and 1 year: effects of antiplatelet therapy. J Am Coll Cardiol 25 (1995) 218-223
7. Yokoya K., Takatsu H., Suzuki T., et al. Process of progression of coronary artery lesions from mild or moderate stenosis to moderate or severe stenosis. A study based on four serial coronary arteriograms per year. Circulation 100 (1999) 903-909
8. Burke A.P., Kolodgie F.D., Farb A., et al. Healed plaque ruptures and sudden coronary death. Evidence that subclinical rupture has a role in plaque progression. Circulation 103 (2001) 934-940
9. De Feyter P.J., Ozaki Y., Baptista J., et al. Ischemia-related lesion characteristics in patients with stable or unstable angina: a study with intracoronary angioscopy and ultrasound. Circulation 92 (1995) 1408-1413
10. Chesebro J.H., Webster M.W.I., Zoldhelyi P., et al. Antithrombotic therapy and progression of coronary artery disease. Antiplatelet versus antithrombins. Circulation 86 (1992) III100-III110
11. White H.D., Norris R.M., Brown M.A., et al. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 317 (1987) 850-855
12. White H.D., Rivers J.T., Maslowski A.H., et al. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med 320 (1989) 817-821
13. CASS investigators. A multicenter comparison of the effects of randomized medical and surgical treatment of mildly symptomatic patients with coronary artery disease, and a registry of consecutive patients undergoing coronary angiography. Circulation 63 Suppl I (1981) I1-I81
14. White H.D., Norris R.M., Brown M.A., et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76 (1987) 44-51
15. French J.K., Ellis C.J., Webber B.J., et al. Abnormal coronary flow in infarct arteries 1 year after myocardial infarction is predicted at 4 weeks by corrected thrombolysis in myocardial infarction (TIMI) frame court and stenosis severity. Am J Cardiol 81 (1998) 665-671
16. Ormiston J.A., Stewart F.M., Roche A.H., et al. Late regression of the dilated site after angioplasty: a 5-year quantitative angiographic study. Circulation 96 (1997) 468-474
17. Waters D., and Pedersen T.R. Review of cholesterol-lowering therapy: coronary angiographic and events trials. Am J Med 101 Suppl 4A (1996) 34s-39s
18. Califf R.M., Pieper K.S., Lee K.L., et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 101 (2000) 2231-2238
19. Goldman S., Copeland J., Moritz T., et al. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: results of a Veterans Administration Cooperative Study. Circulation 77 (1988) 1324-1332
20. van der Meer J., Hillege H.L., van Gilst W.H., et al. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 342 (1993) 257-264
21. Ericsson C.G., Hamsten A., Nilsson J., et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 347 (1996) 849-853
22. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
23. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1067-1075
24. Azen S.P., Mack W.J., Cashin-Hemphill L., et al. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study. Circulation 93 (1996) 34-41
25. Fox K.M., and and the European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362 (2003) 782-788
26. GISSI-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999) 447-455
27. Cashin-Hemphill L., Holmvang G., Chan R.C., et al. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Am J Cardiol 83 (1999) 43-47
28. Sacks F.M., Stone P.H., Gibson C.M., et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. J Am Coll Cardiol 25 (1995) 1492-1498
29. Glagov S., Weisenberg E., Zarins C.K., et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 316 (1987) 1371-1375
30. Goldstein J.A., Demetriou D., Grines C., et al. Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343 (2000) 915-922